903 related articles for article (PubMed ID: 34111271)
1. Report of the National Institutes of Health SARS-CoV-2 Antiviral Therapeutics Summit.
Hall MD; Anderson JM; Anderson A; Baker D; Bradner J; Brimacombe KR; Campbell EA; Corbett KS; Carter K; Cherry S; Chiang L; Cihlar T; de Wit E; Denison M; Disney M; Fletcher CV; Ford-Scheimer SL; Götte M; Grossman AC; Hayden FG; Hazuda DJ; Lanteri CA; Marston H; Mesecar AD; Moore S; Nwankwo JO; O'Rear J; Painter G; Singh Saikatendu K; Schiffer CA; Sheahan TP; Shi PY; Smyth HD; Sofia MJ; Weetall M; Weller SK; Whitley R; Fauci AS; Austin CP; Collins FS; Conley AJ; Davis MI
J Infect Dis; 2021 Jul; 224(Supplement_1):S1-S21. PubMed ID: 34111271
[TBL] [Abstract][Full Text] [Related]
2. Viral Proteases as Targets for Coronavirus Disease 2019 Drug Development.
Zhu W; Shyr Z; Lo DC; Zheng W
J Pharmacol Exp Ther; 2021 Aug; 378(2):166-172. PubMed ID: 33972366
[TBL] [Abstract][Full Text] [Related]
3. Current approaches for target-specific drug discovery using natural compounds against SARS-CoV-2 infection.
Khare P; Sahu U; Pandey SC; Samant M
Virus Res; 2020 Dec; 290():198169. PubMed ID: 32979476
[TBL] [Abstract][Full Text] [Related]
4. Effects of simeprevir on the replication of SARS-CoV-2 in vitro and in transgenic hACE2 mice.
Muturi E; Hong W; Li J; Yang W; He J; Wei H; Yang H
Int J Antimicrob Agents; 2022 Jan; 59(1):106499. PubMed ID: 34929295
[TBL] [Abstract][Full Text] [Related]
5. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.
Artese A; Svicher V; Costa G; Salpini R; Di Maio VC; Alkhatib M; Ambrosio FA; Santoro MM; Assaraf YG; Alcaro S; Ceccherini-Silberstein F
Drug Resist Updat; 2020 Dec; 53():100721. PubMed ID: 33132205
[TBL] [Abstract][Full Text] [Related]
6. COVID-19 therapeutics: Small-molecule drug development targeting SARS-CoV-2 main protease.
Kronenberger T; Laufer SA; Pillaiyar T
Drug Discov Today; 2023 Jun; 28(6):103579. PubMed ID: 37028502
[TBL] [Abstract][Full Text] [Related]
7. TMPRSS2 and RNA-Dependent RNA Polymerase Are Effective Targets of Therapeutic Intervention for Treatment of COVID-19 Caused by SARS-CoV-2 Variants (B.1.1.7 and B.1.351).
Lee J; Lee J; Kim HJ; Ko M; Jee Y; Kim S
Microbiol Spectr; 2021 Sep; 9(1):e0047221. PubMed ID: 34378968
[TBL] [Abstract][Full Text] [Related]
8. An all-out assault on SARS-CoV-2 replication.
Hay RT
Biochem J; 2021 Jul; 478(13):2399-2403. PubMed ID: 34198321
[TBL] [Abstract][Full Text] [Related]
9. Cellular host factors for SARS-CoV-2 infection.
Baggen J; Vanstreels E; Jansen S; Daelemans D
Nat Microbiol; 2021 Oct; 6(10):1219-1232. PubMed ID: 34471255
[TBL] [Abstract][Full Text] [Related]
10. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL
Froggatt HM; Heaton BE; Heaton NS
J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534
[TBL] [Abstract][Full Text] [Related]
11. Precision therapeutic targets for COVID-19.
Krumm ZA; Lloyd GM; Francis CP; Nasif LH; Mitchell DA; Golde TE; Giasson BI; Xia Y
Virol J; 2021 Mar; 18(1):66. PubMed ID: 33781287
[TBL] [Abstract][Full Text] [Related]
12. Bioactive Terpenes and Their Derivatives as Potential SARS-CoV-2 Proteases Inhibitors from Molecular Modeling Studies.
Diniz LRL; Perez-Castillo Y; Elshabrawy HA; Filho CDSMB; de Sousa DP
Biomolecules; 2021 Jan; 11(1):. PubMed ID: 33430299
[TBL] [Abstract][Full Text] [Related]
13. Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19.
Unoh Y; Uehara S; Nakahara K; Nobori H; Yamatsu Y; Yamamoto S; Maruyama Y; Taoda Y; Kasamatsu K; Suto T; Kouki K; Nakahashi A; Kawashima S; Sanaki T; Toba S; Uemura K; Mizutare T; Ando S; Sasaki M; Orba Y; Sawa H; Sato A; Sato T; Kato T; Tachibana Y
J Med Chem; 2022 May; 65(9):6499-6512. PubMed ID: 35352927
[TBL] [Abstract][Full Text] [Related]
14. Current state of vaccine development and targeted therapies for COVID-19: impact of basic science discoveries.
Marian AJ
Cardiovasc Pathol; 2021; 50():107278. PubMed ID: 32889088
[TBL] [Abstract][Full Text] [Related]
15. Iterated Virtual Screening-Assisted Antiviral and Enzyme Inhibition Assays Reveal the Discovery of Novel Promising Anti-SARS-CoV-2 with Dual Activity.
Hamdy R; Fayed B; Mostafa A; Shama NMA; Mahmoud SH; Mehta CH; Nayak Y; M Soliman SS
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445763
[TBL] [Abstract][Full Text] [Related]
16. Overview of antiviral drug candidates targeting coronaviral 3C-like main proteases.
Chen CC; Yu X; Kuo CJ; Min J; Chen S; Ma L; Liu K; Guo RT
FEBS J; 2021 Sep; 288(17):5089-5121. PubMed ID: 33400393
[TBL] [Abstract][Full Text] [Related]
17.
Liu H; Ye F; Sun Q; Liang H; Li C; Li S; Lu R; Huang B; Tan W; Lai L
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):497-503. PubMed ID: 33491508
[TBL] [Abstract][Full Text] [Related]
18. The biogenesis of SARS-CoV-2 spike glycoprotein: multiple targets for host-directed antiviral therapy.
Santopolo S; Riccio A; Santoro MG
Biochem Biophys Res Commun; 2021 Jan; 538():80-87. PubMed ID: 33303190
[TBL] [Abstract][Full Text] [Related]
19. Hundreds of COVID trials could provide a deluge of new drugs.
Ledford H
Nature; 2022 Mar; 603(7899):25-27. PubMed ID: 35233098
[No Abstract] [Full Text] [Related]
20. Pharmacological inhibition of fatty acid synthesis blocks SARS-CoV-2 replication.
Chu J; Xing C; Du Y; Duan T; Liu S; Zhang P; Cheng C; Henley J; Liu X; Qian C; Yin B; Wang HY; Wang RF
Nat Metab; 2021 Nov; 3(11):1466-1475. PubMed ID: 34580494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
